

Axial spondyloarthritis as a paraneoplastic syndrome (clinical case)
https://doi.org/10.33667/2078-5631-2024-29-61-64
Abstract
The article reports the problems of rheumatic disease as paraneoplastic syndrome. It includes the description of the clinical case of axial spondyloarthritis as paraneoplastic syndrome related to the neuroendocrine tumor of the duodenum. In this case, axial spondyloarthritis was characterized by rapid involvement of peripheral and axial symptoms, high acute phase reactants, resistance to drug therapy and reduction of clinical and laboratory symptoms after treatment for neuroendocrine tumor. In differential diagnostics of and paraneoplastic rheumatic disease, it is necessary to pay attention for the time of occurrence of rheumatic symptoms, clinical symptoms before and after surgical and non-surgical treatment for cancer, response to drug therapy, family cancer anamnesis, exposure to carcinogens, previous immunosuppressive therapy, as well as severity of general constitutional symptoms, atypical manifestations of rheumatic disease, age of disease debut over 50 years.
About the Authors
E. Yu. AkulinushkinaRussian Federation
Ekaterina. Yu. Akulinushkina, rheumatologist, assistant professor
Dept of Rheumatology; Department of Hospital Therapy
Izhevsk
E. F. Iskhakova
Russian Federation
El′mira. F. Iskhakova, rheumatologist
Dept of Rheumatology
Izhevsk
S. P. Yakupova
Russian Federation
Svetlana P. Yakupova, PhD Med, associate professor, chief freelance specialist rheumatologist of the Ministry of Health of Tatarstan Republic
Kazan
References
1. de Figueiredo I. R., Alves R. V., Sara S. G. et al. Rheumatologic Diseases as Paraneoplastic Syndromes – A Paradigmatic Case. Journal of Rheumatic Diseases and Treatment. 2018; 4: 067. DOI: 10.23937/2469-5726/1510067
2. Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Seminars in Diagnostic Pathology. 2019; 36 (4): 204–210. DOI: 10.1053/j.semdp.2019.01.002
3. Pelosof L. C., Gerber D. E. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clinic Proceedings. 2010; 85 (9): 838–54.
4. Zuliani L., Graus F., Giometto B. et al. Central nervous system neuronal surface antibody associated syndromes : review and guidelines for recognition. Journal of Neurology, Neurosurgery and Psychiatry. 2012; 83 (6): 638–45.
5. Honnorat J., Viaccoz A. New concepts in paraneoplastic neurological syndromes. The Revue neurologique (Paris). 2011; 167 (10): 729–36.
6. Nathanson L., Hall TC. Introduction: paraneoplastic syndromes. Seminars in Oncology. 1997; 24: 265–268.
7. Lila A. M., Dubinina T. V., Dreval R. O. et al. Medical and social significance and calculation of the economic burden of axial spondyloarthritis in the Russian Federation. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022; 16 (1): 20–25. (In Russ.). DOI: 10.14412/1996-7012-2022-1-20-25
8. Order of the Ministry of Health of the Russian Federation of November 7, 2012 № 687n «The approval of the standard of specialized medical care for ankylosing spondylitis, psoriatic arthritis, and other spondyloarthritides». (In Russ.).
9. Jesus G., Barcelos A., Neves C., et al. Manifestações Reumáticas e Neoplasias. Acta Reumatológica Portuguesa. 2006; 31: 305–321.
10. Sendur O. Paraneoplastic Rheumatic Disorders. The Journal of Turkish Society for Rheumatology. 2012; 27: 18–23.
11. Karmacharya P., Shahukhal R., Ogdie A. Risk of Malignancy in Spondyloarthritis : A Systematic Review. Rheumatic Disease Clinics of North America. 2020; 46 (3): 463–511. DOI: 10.1016/j.rdc.2020.04.001
12. Chang C. C., Chang C. W., Nguyen P. A. et al. Ankylosing spondylitis and the risk of cancer. Oncology Letters. 2017; 14 (2): 1315–1322. DOI: 10.3892/ol.2017.6368
13. Luo X., Deng C., Fei Y. et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2019; 48 (4): 626–631. DOI: 10.1016/j.semarthrit.2018.05.009
14. Deng C., Li W., Fei Y. et al. Risk of malignancy in ankylosing spondylitis : a systematic review and meta-analysis. Scientific Reports. 2016; 6: 32063. DOI: 10.1038/srep32063
15. Carmona L., Abasolo L., Descalzo M. A., et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Seminars in Arthritis and Rheumatism. 2011; 41 (1): 71–80. DOI: 10.1016/j.semarthrit.2010.08.005
Review
For citations:
Akulinushkina E.Yu., Iskhakova E.F., Yakupova S.P. Axial spondyloarthritis as a paraneoplastic syndrome (clinical case). Medical alphabet. 2024;(29):61-64. (In Russ.) https://doi.org/10.33667/2078-5631-2024-29-61-64